These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 16929262)
1. Light shed on battle against HIV. Check E Nature; 2006 Aug; 442(7105):852-3. PubMed ID: 16929262 [No Abstract] [Full Text] [Related]
2. Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? Fazekas de St Groth B; Landay AL AIDS; 2008 Mar; 22(6):671-83. PubMed ID: 18356596 [No Abstract] [Full Text] [Related]
3. Immunopathogenesis and immunotherapy in AIDS virus infections. Letvin NL; Walker BD Nat Med; 2003 Jul; 9(7):861-6. PubMed ID: 12835706 [TBL] [Abstract][Full Text] [Related]
4. A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. Navis M; Schellens IM; van Swieten P; Borghans JA; Miedema F; Kootstra NA; van Baarle D; Schuitemaker H J Infect Dis; 2008 Mar; 197(6):871-9. PubMed ID: 18279072 [TBL] [Abstract][Full Text] [Related]
5. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever? Egan MA Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741 [No Abstract] [Full Text] [Related]
6. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793 [TBL] [Abstract][Full Text] [Related]
12. Measuring HIV-1-specific T cell immunity: how valid are current assays? D'Souza MP; Altfeld M J Infect Dis; 2008 Feb; 197(3):337-9. PubMed ID: 18184092 [No Abstract] [Full Text] [Related]
13. [A new therapeutic strategy to control HIV? The PD1 molecule and its role in inhibiting cellular immune responses]. Iglesias-Chiesa MC; Crabtree-Ramírez B; Reyes-Terán G Gac Med Mex; 2008; 144(1):75-8. PubMed ID: 18619062 [TBL] [Abstract][Full Text] [Related]
14. Accessories for naked DNA vaccines. Levitsky HI Nat Biotechnol; 1997 Jul; 15(7):619-20. PubMed ID: 9219258 [No Abstract] [Full Text] [Related]
15. HIV vaccine efficacy trials: towards the future of HIV prevention. Kim D; Elizaga M; Duerr A Infect Dis Clin North Am; 2007 Mar; 21(1):201-17, x. PubMed ID: 17502236 [TBL] [Abstract][Full Text] [Related]
16. Editorial: Is HIV-1 induction of macrophage expression of PD-L1 and PD-L2 its weakest or strongest link to disease? HIV-1 plays both sides by augmenting and limiting T cell activation to survive in vivo. Patro SC; Montaner LJ J Leukoc Biol; 2011 Apr; 89(4):495-8. PubMed ID: 21454360 [No Abstract] [Full Text] [Related]
17. HIV versus cytotoxic T lymphocytes--the war being lost. Oldstone MB N Engl J Med; 1997 Oct; 337(18):1306-8. PubMed ID: 9345083 [No Abstract] [Full Text] [Related]
18. No vaccine against HIV yet--are we not perfectly equipped? Singh M Virol J; 2006 Aug; 3():60. PubMed ID: 16939652 [TBL] [Abstract][Full Text] [Related]
19. The role of human leukocyte antigen E and G in HIV infection. Tripathi P; Agrawal S AIDS; 2007 Jul; 21(11):1395-404. PubMed ID: 17589185 [No Abstract] [Full Text] [Related]
20. Generation of HIV-1-specific T cells by electroporation of T-cell receptor RNA. Hofmann C; Harrer T; Kubesch V; Maurer K; Metzner KJ; Eismann K; Bergmann S; Schmitt-Haendle M; Schuler G; Dörrie J; Schaft N AIDS; 2008 Aug; 22(13):1577-82. PubMed ID: 18670216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]